Join Molly Borchardt, PharmD, and Erin Lopata, PharmD, MPH, from the Precision Access Experience Team, as they unveil crucial insights that can help enhance your access strategy.
Rare diseases, impacting fewer than 200,000 individuals in the US, present daunting access and reimbursement obstacles, with 95% lacking approved therapy. As the median treatment cost exceeds $200,000 annually, concerns about affordability, access, and value persist for over 10,000 identified rare diseases, affecting 30 million Americans.
